Keywords: Watson, Uteron Pharma, M&A, Contraception, Infertility, Opana, Patent challenge, Endo, Grunenthal
Watson acquires Uteron Pharma; confirms Opana patent challenge
Article | 24 January 2013
US generic and specialty drugmaker Watson Pharmaceuticals (NYSE: WPI) says that it has completed the acquisition of Belgium-based Uteron Pharma ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
